Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroda International Regulatory News (CRDA)

Share Price Information for Croda International (CRDA)

Share Price is delayed by 15 minutes
Get Live Data
3179.00    95.00 (3.08%)
Bid:
3186.00
Ask:
3188.00
Spread: 2.00 (0.063%)
Market Cap: £4.43b
CRDA Live PriceLast checked at - London Stock Exchange

Intraday Croda International Share Chart

Acquisition

24 May 2013 07:00

RNS Number : 4809F
Croda International PLC
24 May 2013
 



24 May 2013

 

Croda International Plc

 

Acquisition ofSpecialty Products Business from Arizona Chemical

Naturally derived polyamides expand Croda's broad portfolio of effects

 

Croda International Plc announces today that it has completed the acquisition of the Specialty Products business of Arizona Chemical based in Jacksonville, Florida in the USA. 

 

The acquisition adds a portfolio of class leading oil gelling polymers to Croda's business and further expands its footprint in the polymers arena, while strengthening Croda's leading position in speciality chemicals derived from renewable resources. The technologies and products of the acquired business are naturally derived polyamides with high bio-renewable content, covered by a range of patents.

 

Keith Layden, Croda's Chief Technology Officer, said:

 

"This acquisition represents further progress in our strategy to acquire complementary new technologies. The varied functionality of these specialised polyamides will be a valuable addition to our offerings across both the Consumer Care and Performance Technologies market sectors. In addition, there are a number of opportunities to further differentiate the technology and create value for ourselves and our customers."

 

No manufacturing assets will be acquired as part of this transaction and Croda will immediately commence the relocation of the products to Croda's Mevisa manufacturing site in Spain and when ready, re-launch the products with new trade names and marketing identities.

 

For further information please contact:

 

Keith Layden, Chief Technology Officer Tel: 01405 860 551

Sean Christie, Group Finance Director

 

Charles Armitstead / Rosie Oddy, Pendomer Communications Tel: 020 3603 5224 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQAJMATMBJTBFJ
Date   Source Headline
4th Aug 20253:21 pmRNSDirector/PDMR Shareholding
4th Aug 202511:03 amRNSDirector/PDMR Shareholding
4th Aug 20258:46 amRNSDirector/PDMR Shareholding
1st Aug 20253:43 pmRNSDirector/PDMR Shareholding
1st Aug 20251:31 pmRNSDirector/PDMR Shareholding
31st Jul 20253:42 pmRNSDirector/PDMR Shareholding
29th Jul 20252:33 pmRNSDirector/PDMR Shareholding
29th Jul 20252:31 pmRNSDirector/PDMR Shareholding
29th Jul 20257:00 amRNSResults for the six months ended 30 June 2025
16th Jul 20252:08 pmRNSDirector/PDMR Shareholding
12th Jun 202510:01 amRNSDirector/PDMR Shareholding
6th Jun 20258:45 amRNSCorporate Broker Appointment
2nd Jun 20258:44 amRNSDirector/PDMR Shareholding
29th May 20258:57 amRNSDirector/PDMR Shareholding
13th May 20253:48 pmRNSDirector/PDMR Shareholding
6th May 20252:26 pmRNSDirector/PDMR Shareholding
24th Apr 202511:40 amRNSResult of AGM
23rd Apr 20257:00 amRNSFirst quarter 2025 sales update
11th Apr 20252:33 pmRNSDirector/PDMR Shareholding
11th Apr 20252:06 pmRNSDirector/PDMR Shareholding
7th Apr 202511:14 amRNSDirector/PDMR Shareholding
4th Apr 20253:49 pmRNSDirector/PDMR Shareholding
3rd Apr 20253:47 pmRNSDirector/PDMR Shareholding
31st Mar 202512:14 pmRNSDirector/PDMR Shareholding
27th Mar 20259:57 amRNSDirector Declaration
25th Mar 202512:30 pmRNSDirector/PDMR Shareholding
25th Mar 202512:27 pmRNSDirector/PDMR Shareholding
25th Mar 202512:26 pmRNSDirector/PDMR Shareholding
25th Mar 202512:23 pmRNSDirector/PDMR Shareholding
25th Mar 202512:21 pmRNSDirector/PDMR Shareholding
25th Mar 202512:21 pmRNSDirector/PDMR Shareholding
25th Mar 202512:17 pmRNSDirector/PDMR Shareholding
25th Mar 202512:14 pmRNSDirector/PDMR Shareholding
13th Mar 202512:38 pmRNSAnnual Financial Report
11th Mar 20252:54 pmRNSDirector/PDMR Shareholding
11th Mar 20257:13 amRNSDirector Declaration
10th Mar 202510:42 amRNSHolding(s) in Company
3rd Mar 20253:49 pmRNSDirectorate Change
25th Feb 202511:30 amRNSDirector/PDMR Shareholding
25th Feb 20257:00 amRNSFinal Results
11th Feb 20253:12 pmRNSDirector/PDMR Shareholding
13th Jan 20252:19 pmRNSDirector/PDMR Shareholding
11th Dec 20243:09 pmRNSDirector/PDMR Shareholding
11th Dec 20241:54 pmRNSDirector/PDMR Shareholding
9th Dec 20242:36 pmRNSHolding(s) in Company
29th Nov 202412:12 pmRNSHolding(s) in Company
20th Nov 20241:42 pmRNSDirector/PDMR Shareholding
19th Nov 20247:00 amRNSDirectorate Change
12th Nov 20242:47 pmRNSDirector/PDMR Shareholding
11th Nov 20247:00 amRNSThird quarter 2024 sales update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.